AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 39186143
Drug: Background therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Background therapy alone
Trial: 39186315
Drug: Any other
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any other therapy
Trial: 39186326
Drug: Bone-anchored hearing
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone-anchored hearing implant surgery using the MONO procedure
Trial: 39186380
Drug: Adipose-Derived Mesenchymal
RxNorm normalized name: Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins
DrugBank: Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins (DB15729)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adipose-Derived Mesenchymal Stem Cell (ADR-001) Therapy
Trial: 39186770
Drug: Enhanced usual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced usual care (single microgrant plus monthly financial literacy education)
Trial: 39186770
Drug: Extended microgrants
RxNorm normalized name: Extramel microgranules
DrugBank: Muskmelon (DB15611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended microgrants (enhanced usual care plus monthly microgrants)
Trial: 39187401
Drug: Neratinib 240
RxNorm normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Neratinib 240 mg once daily for up to 1 year
Trial: 39187595
Drug: anti-TIGIT antibody
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: anti-TIGIT antibody
Trial: 39187595
Drug: anti-LAG3 antibody
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: anti-LAG3 antibody
Trial: 39188412
Drug: Balance chiropractic
RxNorm normalized name: Rebalance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balance chiropractic therapy (BCT) for 20 days
Trial: 39188940
Drug: Transdiagnostic group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdiagnostic group treatment protocol administered in a blended format
Trial: 39188943
Drug: FCN-437c 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FCN-437c 400 mg
Trial: 39188996
Drug: Positron emission
RxNorm normalized name: propofol lipid emulsion Injection [Propoven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positron emission tomography/computed tomography after intravenous administration of 296 MBq
Trial: 39189858
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 1200 mg orally twice daily for days 1 to 112
Trial: 39189858
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy without NAC
Trial: 39190445
Drug: Growing engagement
RxNorm normalized name: minoxidil
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Growing engagement in therapy
Trial: 39190534
Drug: Nivolumab monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab monotherapy for CD8-high patients (CD8 ≥15%)
Trial: 39191745
Drug: CoronaVac booster
RxNorm normalized name: CoronaVac
DrugBank: CoronaVac (DB15806)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoronaVac booster (CC-C)
Trial: 39191745
Drug: CoronaVac (CC-C)
RxNorm normalized name: CoronaVac
DrugBank: CoronaVac (DB15806)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoronaVac (CC-C)
Trial: 39191745
Drug: BNT162b2 (CC-B)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNT162b2 (CC-B)
Trial: 39191755
Drug: Vactosertib (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vactosertib (200 mg twice daily) in combination with pomalidomide
Trial: 39191809
Drug: Inhaled enriched
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled enriched heparin
Trial: 39192162
Drug: Pentoxifylline (PTX)
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (PTX) 400 mg two times daily for 24 weeks
Trial: 39192162
Drug: Mesalamine 1
RxNorm normalized name: mesalamine 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesalamine 1 g t.i.d. for 24 weeks (Control)
Trial: 39193207
Drug: As-needed albuterol-budesonide
RxNorm normalized name: albuterol / budesonide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As-needed albuterol-budesonide 180/160 µg pressurized metered-dose inhaler (pMDI)
Trial: 39193463
Drug: Electroacupuncture (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture (EA) in addition to conventional medication, 12 EA sessions over 6 weeks.
Trial: 39193463
Drug: Waiting-list group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waiting-list group receiving only conventional medication.
Trial: 39193655
Drug: 1 mcg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mcg/kg dexmedetomidine
Trial: 39193655
Drug: 0.25 mcg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mcg/kg dexmedetomidine
Trial: 39193655
Drug: 0.5 mcg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mcg/kg dexmedetomidine
Trial: 39194012
Drug: Internet-delivered exposure-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered exposure-based cognitive behavior therapy (ECBT) for 12 weeks
Trial: 39194024
Drug: Watchful waiting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Watchful waiting strategy (no antimicrobial administration for ventilator-associated tracheobronchitis, antimicrobials prescribed only for ventilator-associated pneumonia, sepsis, septic shock, or another infectious diagnosis)
Trial: 39194024
Drug: Routine antimicrobial
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine antimicrobial treatment strategy for seven days
Trial: 39194206
Drug: iAST's first
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iAST's first three antibiotic recommendations
Trial: 39194206
Drug: Doctor's prescribed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doctor's prescribed antibiotics
Trial: 39196551
Drug: n-3 LCPUFA
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 LCPUFA (fish oil) 2.4 g per day until 1 week post partum
Trial: 39198799
Drug: Tiotropium 18
RxNorm normalized name: TIOTROPIUM 18MCG CAP,INHL,6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium 18 mcg via HandiHaler
Trial: 39199994
Drug: RHB-104 (triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RHB-104 (triple antimicrobial therapy)
Trial: 39202082
Drug: Physical Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical Therapy sessions of goal-directed and task-specific training (30 sessions, 3 per week for 10 weeks)
Trial: 39202082
Drug: Usual Physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual Physical Therapy treatment
Trial: 39202581
Drug: Combined Low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined Low Dose of Human Chorionic Gonadotropin (HCG) and Clomiphene Citrate (CC)
Trial: 39202581
Drug: Continued Clomiphene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued Clomiphene Citrate (CC)
Trial: 39203915
Drug: Fermented Soybean
RxNorm normalized name: SOYBEAN
DrugBank: Soybean (DB10568)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fermented Soybean (FSB) Supplementation (1 g once daily for 12 weeks)
Trial: 39206389
Drug: Semaglutide (GLP-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semaglutide (GLP-1 agonist)
Trial: 39206547
Drug: Protein cluster
RxNorm normalized name: cluster fig extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein cluster with tumor necrosis factor receptor 1
Trial: 39206549
Drug: Liberal transfusion
RxNorm normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liberal transfusion strategy (threshold, 10 g/dL)
Trial: 39206549
Drug: Restrictive transfusion
RxNorm normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive transfusion strategy (threshold, 7-8 g/dL)
Trial: 39207239
Drug: Epinephrine delivered
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine delivered via metered-dose inhalation
Trial: 39207239
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of epinephrine
Trial: 39207344
Drug: Nontriptan treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nontriptan treatments
Trial: 39207839
Drug: Inpatient nipple
RxNorm normalized name: Impatiens irvingii whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inpatient nipple stimulation therapy via an electric breast pump
Trial: 39207839
Drug: Immediate synthetic
RxNorm normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate synthetic oxytocin infusion without nipple stimulation
Trial: 39208489
Drug: Treatment-free observation
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-free observation period
Trial: 39209068
Drug: Dupilumab 100/200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab 100/200 mg every 2 weeks
Trial: 39209155
Drug: Leucine intake
RxNorm normalized name: Leucine
DrugBank: Leucine (DB00149)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leucine intake at 7 different levels over a 3-day period after 2 days of preadaptation to adequate protein intake (1.0 g⋅kg)
Trial: 39209187
Drug: Vonoprazan 10
RxNorm normalized name: vonoprazan 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vonoprazan 10 mg once daily
Trial: 39209203
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g gluten per day
Trial: 39209203
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g gluten per day
Trial: 39209369
Drug: Certolizumab pegol
RxNorm normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Certolizumab pegol (CZP) treatment for 12 weeks
Trial: 39209452
Drug: Various immune
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various immune checkpoint inhibitors with (nab-)paclitaxel and platinum-based chemotherapy (Cohort 2, 48 patients)
Trial: 39209452
Drug: Neoadjuvant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant treatment of toripalimab with chemotherapy (Cohort 3, 27 patients)
Trial: 39209495
Drug: Low-exchange SBUF
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-exchange SBUF (L-SBUF) during CPB
Trial: 39209730
Drug: 0.5% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% ropivacaine plus dexamethasone 0.1 mg/kg (DEX0.1)
Trial: 39209730
Drug: 0.5% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% ropivacaine plus dexamethasone 0.05 mg/kg (DEX0.05)
Trial: 39209778
Drug: Antihypertensive deprescribing
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive deprescribing
Trial: 39209781
Drug: methylprednisolone (62.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: methylprednisolone (62.5 mg/mL)
Trial: 39209782
Drug: Sabatolimab 800
RxNorm normalized name: Sabatolimab
DrugBank: Sabatolimab (DB16322)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sabatolimab 800 mg every 4 weeks plus spartalizumab 400 mg every 4 weeks until unacceptable toxicity, disease progression and/or treatment discontinuation.
Trial: 39209823
Drug: mRNA-1273 (50-µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA-1273 (50-µg booster dose)
Trial: 39210194
Drug: Neoadjuvant radio-chemotherapy
RxNorm normalized name: Valerianae radix
DrugBank: Valerian (DB13196)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant radio-chemotherapy (Group 1, 25 cases)
Trial: 39210194
Drug: No neoadjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No neoadjuvant treatment (Group 2, 28 cases)
Trial: 39210194
Drug: Neoadjuvant radio-chemotherapy
RxNorm normalized name: Valerianae radix
DrugBank: Valerian (DB13196)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant radio-chemotherapy (Group 1)
Trial: 39210194
Drug: No neoadjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No neoadjuvant treatment (Group 2)
Trial: 39210314
Drug: Website with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Website with referrals to HIV care and substance use disorder treatment resources
Trial: 39210342
Drug: Shen Que
RxNorm normalized name: Ren shen
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shen Que moxibustion (SQM) + IVF treatment
Trial: 39210342
Drug: IVF treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVF treatment alone (Control)
Trial: 39211540
Drug: Multichannel tDCS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multichannel tDCS targeting the left DLPFC, 37 sessions of 30 minutes each over 8 weeks (4 weeks daily treatment + 4 weeks taper).
Trial: 39211745
Drug: Individually tailored
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individually tailored nutritional guidance from a clinical nutritionist and oral health guidance from a dental hygienist
Trial: 39211865
Drug: Navtemadlin (KRT-232)
RxNorm normalized name: Navtemadlin
DrugBank: Navtemadlin (DB15299)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Navtemadlin (KRT-232) 120 mg daily
Trial: 39211865
Drug: Navtemadlin (KRT-232)
RxNorm normalized name: Navtemadlin
DrugBank: Navtemadlin (DB15299)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Navtemadlin (KRT-232) 240 mg daily
Trial: 39211964
Drug: Intravenous glucocorticoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous glucocorticoid (methylprednisolone, 250 mg)
Trial: 39212246
Drug: Low-dose digoxin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose digoxin
Trial: 39212270
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of RASIs 48 hours prior to surgery (n=1115)
Trial: 39212990
Drug: Early antihypertensive
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early antihypertensive treatment (immediate)
Trial: 39212990
Drug: Delayed antihypertensive
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed antihypertensive treatment (starting on day 8)
Trial: 39212990
Drug: Early antihypertensive
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early antihypertensive treatment (immediate) in patients with PAD
Trial: 39212990
Drug: Delayed antihypertensive
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed antihypertensive treatment (starting on day 8) in patients with PAD
Trial: 39212990
Drug: Early antihypertensive
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early antihypertensive treatment (immediate) in patients without PAD
Trial: 39212990
Drug: Delayed antihypertensive
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed antihypertensive treatment (starting on day 8) in patients without PAD
Trial: 39213138
Drug: Cilofexor (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilofexor (100 mg)
Trial: 39213138
Drug: Firsocostat (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Firsocostat (20 mg)
Trial: 39213187
Drug: Interruption of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interruption of beta-blocker treatment
Trial: 39213187
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of beta-blocker treatment
Trial: 39213194
Drug: Vutrisiran (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vutrisiran (25 mg) every 12 weeks for up to 36 months
Trial: 39213367
Drug: Optilume drug-coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optilume drug-coated balloon (DCB)
Trial: 39214018
Drug: Standard consolidation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard consolidation chemotherapy (SC)
Trial: 39214047
Drug: PF-06952229 monotherapy
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-06952229 monotherapy 375 mg, oral b.i.d., 7 days on/7 days off, 28-day cycles (Part 1A)
Trial: 39214047
Drug: PF-06952229 monotherapy
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-06952229 monotherapy 375 mg
Trial: 39214047
Drug: PF-06952229 monotherapy
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-06952229 monotherapy
Trial: 39214467
Drug: Bepirovirsen 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bepirovirsen 300 mg once weekly for 24 weeks followed by Peg-IFN 180 μg once weekly for up to 24 weeks (Arm 1)
Trial: 39214467
Drug: Bepirovirsen 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bepirovirsen 300 mg once weekly for 12 weeks followed by Peg-IFN 180 μg once weekly for up to 24 weeks (Arm 2)
Trial: 39214467
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy with bepirovirsen followed by Peg-IFN
Trial: 39214801
Drug: Apixaban (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apixaban (5 mg or 2.5 mg per label indication) twice daily
Trial: 39215063
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g of dark chocolate
Trial: 39215531
Drug: Sacubitril/valsartan (Sac/Val)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sacubitril/valsartan (Sac/Val) therapy
Trial: 39215531
Drug: Angiotensin-converting enzyme
RxNorm normalized name: ACE - Angiotensin-converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker (control)
Trial: 39215646
Drug: High-Dose Quadrivalent
RxNorm normalized name: Fluzone High-Dose Quadrivalent PF 2020-2021
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Dose Quadrivalent Influenza Vaccine
Trial: 39215646
Drug: Standard-Dose Quadrivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-Dose Quadrivalent Influenza Vaccine
Trial: 39215793
Drug: Megestrol acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megestrol acetate (MA) 160 mg orally daily
Trial: 39215972
Drug: Tight potassium
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tight potassium control (supplementing if serum potassium concentration fell below 4.5 mEq/L)
Trial: 39215972
Drug: Relaxed potassium
RxNorm normalized name: Potassium
DrugBank: Potassium (DB14500)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relaxed potassium control (supplementing if serum potassium concentration fell below 3.6 mEq/L)
Trial: 39216096
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of oral anticoagulation
Trial: 39216096
Drug: Interruption of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interruption of oral anticoagulation
Trial: 39216092
Drug: Transcatheter mitral-valve
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcatheter mitral-valve repair and guideline-recommended medical therapy (device group)
Trial: 39216107
Drug: Garetosmab 10
RxNorm normalized name: Garetosmab
DrugBank: Garetosmab (DB16379)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Garetosmab 10 mg/kg every 4 weeks for 28 weeks
Trial: 39216478
Drug: ESG401 (Trop2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ESG401 (Trop2 antibody-drug conjugate) at a maximum tolerated dose of 16 mg/kg on days 1, 8, and 15 of a 28-day cycle
Trial: 39216478
Drug: ESG401 (Trop2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ESG401 (Trop2 antibody-drug conjugate) at therapeutically relevant doses
Trial: 39217448
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment (watchful waiting)
Trial: 39217453
Drug: Ertugliflozin 5
RxNorm normalized name: ertugliflozin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ertugliflozin 5 mg once daily
Trial: 39217504
Drug: Zibotentan (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zibotentan (10 mg daily for 12 weeks)
Trial: 39217553
Drug: Semaglutide 1
RxNorm normalized name: semaglutide 14 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semaglutide 1 mg once-weekly subcutaneous injection
Trial: 39217556
Drug: Aficamten (5-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aficamten (5-20 mg daily for 24 weeks)
Trial: 39217563
Drug: Aficamten (5-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aficamten (5-20 mg for 24 weeks)